Brand Name :
Xopenex, Xopenex HFA
Synonyms :
levalbuterol
Class :
Drugs for asthma and COPD & Bronchodilators Frequency defined: >10%: Headache Vomiting Viral infection Rhinitis 1%-10% Tachycardia Nervousness Dizziness Anxiety Pain Skin rash Diarrhea Tremor Weakness Pharyngitis Cough Sinusitis Fever Mucosa swelling
Brand Name :
Xopenex, Xopenex HFA
Synonyms :
levalbuterol
Class :
Drugs for asthma and COPD & Bronchodilators Frequency defined: >10%: Headache Vomiting Viral infection Rhinitis 1%-10% Tachycardia Nervousness Dizziness Anxiety Pain Skin rash Diarrhea Tremor Weakness Pharyngitis Cough Sinusitis Fever Mucosa swelling
Dosage Forms & Strengths
Aerosol, Inhalation:
45 mcg/actuation
Nebulization solution, Inhalation:
0.31mg/3ml
0.63mg/3ml
1.25mg/3ml
1.25mg/0.5ml
Note: 1.25 mg of levalbuterol base is equivalent to 2.5 mg of albuterol.
Metered-dose inhaler: 2 to 4 oral inhalations (45 mcg/actuation) with spacer every 20 minutes for 3 doses
Nebulization solution: 1.25mg to 2.5mg oral inhalation every 20 minutes for 3 doses
Asthma with intermittent symptoms:
Metered-dose inhaler: 2 oral inhalations with a spacer every 4 to 6 hours as needed.
Nebulization solution: 0.63 mg to 1.25 mg oral inhalation every 6 to 8 hours as needed up to 3 doses per 24 hours
chronic obstructive pulmonary disease (COPD)
Nebulization solution: 0.63 mg to 1.25mg oral inhalation every 1 hour for 2 to 3 doses or as needed
Metered-dose inhaler: 1 to 2 oral inhalations every 1 hour for 2 to 3 doses or as needed
Dosage Forms & Strengths
Aerosol, Inhalation:
45 mcg/actuation
Nebulization solution, Inhalation:
0.31mg/3ml
0.63mg/3ml
1.25mg/3ml
1.25mg/0.5ml
Note: 1.25 mg of levalbuterol base is equivalent to 2.5 mg of albuterol.
Metered-dose inhaler: Children >4 years and Adolescents:
2 oral inhalations every 4 to 6 hours as needed
Nebulization:
Infants and Children <4 years: 0.31 to 1.25 mg oral inhalation every 4 to 6 hours as needed
Children 5 to <12 years: 0.31 to 0.63 mg oral inhalation every 8 hours as needed
Children >12 years and adolescents: 0.63 to 1.25mg oral inhalation every 6 to 8 hours as needed
Beta-Blockers decrease the effect of bronchiodilation of Beta2-Agonists
Beta-Blockers decrease the effect of bronchiodilation of Beta2-Agonists
Beta-Blockers decrease the effect of bronchiodilation of Beta2-Agonists
Beta-Blockers decrease the effect of bronchiodilation of Beta2-Agonists
Beta-Blockers decrease the effect of bronchiodilation of Beta2-Agonists
may increase the AV blocking effect of alpha2 agonists
may decrease the bronchodilatory effect
may decrease the bronchodilatory effect
it increases the effect of bradycardia of Beta-Blockers
beta-Blockers may enhance the adverse/toxic effect of cholinergic agonists
beta-Blockers may enhance the adverse/toxic effect of cholinergic agonists
beta-Blockers may enhance the adverse/toxic effect of cholinergic agonists
beta-Blockers may enhance the adverse/toxic effect of cholinergic agonists
beta-Blockers may enhance the adverse/toxic effect of cholinergic agonists
beta-Blockers may enhance the hypoglycemic effect of antidiabetic Agents
beta-Blockers may enhance the hypoglycemic effect of antidiabetic Agents
beta-Blockers may enhance the hypoglycemic effect of antidiabetic Agents
beta-Blockers may enhance the hypoglycemic effect of antidiabetic Agents
beta-Blockers may enhance the hypoglycemic effect of antidiabetic Agents
May enhance the hypotensive effect of beta-Blockers
May enhance the hypotensive effect of beta-Blockers
May enhance the hypotensive effect of beta-Blockers
May enhance the hypotensive effect of beta-Blockers
May enhance the hypotensive effect of beta-Blockers
May enhance the hypotensive effect of beta-Blockers
May enhance the hypotensive effect of beta-Blockers
May enhance the hypotensive effect of beta-Blockers
May enhance the hypotensive effect of beta-Blockers
May enhance the hypotensive effect of beta-Blockers
May enhance the hypotensive effect of beta-Blockers
May enhance the hypotensive effect of beta-Blockers
May enhance the hypotensive effect of beta-Blockers
May enhance the hypotensive effect of beta-Blockers
May enhance the hypotensive effect of beta-Blockers
May enhance the hypotensive effect of beta-Blockers
May enhance the hypotensive effect of beta-Blockers
May enhance the hypotensive effect of beta-Blockers
beta-blockers may enhance the vasoconstricting effect of ergot derivatives
beta-blockers may enhance the vasoconstricting effect of ergot derivatives
beta-blockers may enhance the vasoconstricting effect of ergot derivatives
beta-blockers may enhance the vasoconstricting effect of ergot derivatives
beta-blockers may enhance the vasoconstricting effect of ergot derivatives
beta-Blockers may enhance the hypoglycemic effect of sulfonylureas
beta-Blockers may enhance the hypoglycemic effect of sulfonylureas
beta-Blockers may enhance the hypoglycemic effect of sulfonylureas
beta-Blockers may enhance the hypoglycemic effect of sulfonylureas
beta-Blockers may enhance the hypoglycemic effect of sulfonylureas
may enhance the orthostatic hypotensive effect of alpha1-blockers
bunazosin (Not available in the United States)
may enhance the orthostatic hypotensive effect of alpha1-blockers
may enhance the orthostatic hypotensive effect of alpha1-blockers
may enhance the orthostatic hypotensive effect of alpha1-blockers
may enhance the orthostatic hypotensive effect of alpha1-blockers
may enhance the hypoglycemic effect of antidiabetic agents
may enhance the hypoglycemic effect of antidiabetic agents
may enhance the hypoglycemic effect of antidiabetic agents
may reduce the antihypertensive effect of beta-blockers
may reduce the antihypertensive effect of beta-blockers
may reduce the antihypertensive effect of beta-blockers
may reduce the antihypertensive effect of beta-blockers
may reduce the antihypertensive effect of beta-blockers
beta-blockers may increase the hypoglycemic effect of antidiabetic agents
beta-blockers may increase the hypoglycemic effect of antidiabetic agents
beta-blockers may increase the hypoglycemic effect of antidiabetic agents
beta-blockers may increase the hypoglycemic effect of antidiabetic agents
beta-blockers may increase the hypoglycemic effect of antidiabetic agents
may increase the hypotensive effect of beta-blockers
may increase the hypotensive effect of beta-blockers
may increase the hypotensive effect of beta-blockers
may increase the hypotensive effect of beta-blockers
may increase the hypotensive effect of beta-blockers
may increase the hypotensive effect of beta-blockers
may increase the hypotensive effect of beta-blockers
may increase the hypotensive effect of beta-blockers
may increase the hypotensive effect of beta-blockers
may increase the hypotensive effect of beta-blockers
may increase the hypotensive effect of beta-blockers
may increase the hypotensive effect of beta-blockers
may increase the hypotensive effect of beta-blockers
may increase the hypotensive effect of beta-blockers
may increase the hypotensive effect of beta-blockers
may increase the hypotensive effect of beta-blockers
may increase the hypotensive effect of beta-blockers
may increase the hypotensive effect of beta-blockers
may increase the hypoglycemic effect
may increase the hypoglycemic effect
may increase the hypoglycemic effect
it increases the effect of hypoglycemia of antidiabetic agents
it increases the effect of hypoglycemia of antidiabetic agents
it increases the effect of hypoglycemia of antidiabetic agents
may enhance the adverse/toxic effect of Cholinergic agonists
may enhance the adverse/toxic effect of Cholinergic agonists
may enhance the adverse/toxic effect of Cholinergic agonists
may enhance the adverse/toxic effect of Cholinergic agonists
may enhance the adverse/toxic effect of Cholinergic agonists
may increase the effect of alpha1-blockers
bunazosin (Not available in the United States)
may increase the effect of alpha1-blockers
may increase the effect of alpha1-blockers
may increase the effect of alpha1-blockers
may increase the effect of alpha1-blockers
may increase the effect of antidiabetic agents
may increase the effect of antidiabetic agents
may increase the effect of antidiabetic agents
may increase the effect of antidiabetic agents
may increase the effect of antidiabetic agents
may increase the adverse effect of cholinergic agonists
may increase the adverse effect of cholinergic agonists
may increase the adverse effect of cholinergic agonists
may increase the adverse effect of cholinergic agonists
may increase the adverse effect of cholinergic agonists
may increase the effect of ergot derivatives
may increase the effect of ergot derivatives
may increase the effect of ergot derivatives
may increase the effect of ergot derivatives
may increase the effect of ergot derivatives
may increase the effect of insulins
may increase the effect of insulins
may increase the effect of insulins
may increase the effect of insulins
may increase the effect of insulins
may enhance the effect of sulfonylureas
may enhance the effect of sulfonylureas
may enhance the effect of sulfonylureas
may enhance the effect of sulfonylureas
may enhance the effect of sulfonylureas
acetylcholinesterase Inhibitors May enhance the bradycardic effect of beta-Blockers
acetylcholinesterase Inhibitors May enhance the bradycardic effect of beta-Blockers
acetylcholinesterase Inhibitors May enhance the bradycardic effect of beta-Blockers
acetylcholinesterase Inhibitors May enhance the bradycardic effect of beta-Blockers
acetylcholinesterase Inhibitors May enhance the bradycardic effect of beta-Blockers
amiodarone may enhance the bradycardic effect of beta-blockers
may increase the bradycardic effect of beta-blockers
may increase the bradycardic effect of beta-blockers
may increase the bradycardic effect of beta-blockers
may increase the bradycardic effect of beta-blockers
may increase the bradycardic effect of beta-blockers
may increase the av-blocking effect of beta-blockers
may increase the av-blocking effect of beta-blockers
may increase the av-blocking effect of beta-blockers